Comparison · NCT01825512-9fa26f0a
Deferiprone vs Deferasirox: Percentage of Successfully Chelated Patients
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Deferiprone vs Deferasirox: Percentage of Successfully Chelated Patients. Trial comparisons, record NCT01825512-9fa26f0a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01825512-9fa26f0a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.552 | 0.465 | 0.636 | wilson | |
| Risk in group 2 | 0.548 | 0.467 | 0.626 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00405 | -0.113 | 0.121 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.812 | 1.25 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.629 | 1.64 | log | |
| Number needed to treat, for one more participant with the outcome on Deferiprone than on Deferasirox | 247 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Deferiprone | 75-100 mg/kg/day seven days per week~Deferiprone: Deferiprone 80 mg/mL oral solution | 69 | 125 | OG000 |
| Group 2 | Deferasirox | 20 to 40 mg/kg/day seven days per week~Deferasirox: Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg | 80 | 146 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Percentage of Successfully Chelated Patients
- Description
Percentage of successfully chelated patients is assessed by serum ferritin levels (in all patients) and cardiac MRI T2\* (in patients above 10 years of age able to perform an MRI scan without sedation)
- Time frame
- at baseline and after 12 months
- Population
- Per-protocol population 1 (PP1): number of patients for whom the primary composite efficacy endpoint data were available at baseline and after 1 year of treatment (271 subjects)
Source ClinicalTrials.gov
Trial
- Title
- Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
- NCT number
- NCT01825512
- Phases
- PHASE3
- Conditions
- Chronic Iron Overload
- Interventions
- Deferiprone, Deferasirox
- Lead sponsor
- Consorzio per Valutazioni Biologiche e Farmacologiche
- Results first posted
- 2021-04-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01825512?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01825512-9fa26f0a